Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases

Area of Science:

• Hepatology
• Immunology
• Molecular Biology

Background:

• The role of interleukin 6 (IL-6) in liver disease pathogenesis is not fully understood.
• IL-6 expression and plasma levels are elevated in patients with acute and chronic liver diseases.
• Elevated IL-6 correlates with impaired liver function, inflammation, portal hypertension, and fibrosis.

Purpose of the Study:

• To investigate the specific contribution of IL-6 signaling to liver disease.
• To elucidate the role of gp130, the IL-6 family cytokine signal transducer, in liver injury and fibrosis.
• To differentiate the effects of IL-6 signaling in hepatocytes versus non-parenchymal liver cells.

Main Methods:

• Analysis of IL-6 expression and plasma levels in liver disease patients.
• Utilized a tetrachlorcarbonide (CCl(4)) induced chronic liver injury model in conditional gp130 knockout mice (AlfpCre and MxCre).
• Assessed STAT3 activation, acute phase response, hepatocyte proliferation, liver injury, and fibrosis progression.

Main Results:

• gp130 deletion abolished STAT3 activation and acute phase response but did not affect acute liver injury or hepatocyte proliferation.
• Deletion of gp130 in hepatocytes had no impact on liver injury or fibrosis.
• Deletion of gp130 in non-parenchymal liver cells exacerbated fibrosis progression during chronic CCl(4) injury.

Conclusions:

• IL-6 is involved in the pathogenesis of liver diseases.
• IL-6/gp130-dependent pathways in non-parenchymal liver cells play a protective role against fibrosis progression in chronic liver diseases.
• Targeting IL-6 signaling in non-parenchymal cells may offer therapeutic potential for liver fibrosis.